Analysts Offer Insights on Healthcare Companies: ObsEva SA (NASDAQ: OBSV) and Immune Design (NASDAQ: IMDZ)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ObsEva SA (NASDAQ:OBSV) and Immune Design (NASDAQ:IMDZ) with bullish sentiments.

ObsEva SA (OBSV)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $44. The company’s shares closed yesterday at $12.49.

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.1% and a 43.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on ObsEva SA is a Strong Buy with an average price target of $32.17, implying a 157.6% upside from current levels. In a report issued on August 15, Leerink Partners also assigned a Buy rating to the stock with a $25 price target.

.

See today’s analyst top recommended stocks >>

Immune Design (IMDZ)

H.C. Wainwright analyst Joseph Pantginis initiated coverage with a Buy rating on Immune Design today and set a price target of $11. The company’s shares closed yesterday at $3.40, close to its 52-week low of $2.80.

Pantginis noted:

“Valuation and risks to price target achievement. We are instituting a Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our model currently only includes the lead indications for CMB305 for sarcoma (30% contribution) and G100 in follicular NHL (70% contribution). We believe upside potential exists as the company explores additional tumor indications for both lead assets, as well as potential contribution from pipeline development.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -10.1% and a 33.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Immune Design is a Moderate Buy with an average price target of $7.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.